Part 1 of 2

Acne Is Not a Sebum Excess Problem

Why Eradicating Sebum Misses the Real Pathology

In medical aesthetics, acne is still frequently framed as a disease of excess sebum. This belief underpins a growing number of treatments and devices designed to aggressively suppress, damage or eradicate sebaceous activity, sometimes driving sebum output towards near zero.

This approach is not just simplistic. It is biologically misguided.

Acne does not begin because sebum exists. Acne escalates because sebum is trapped within an obstructed follicle and then biochemically degraded, triggering inflammation.

No obstruction. No lesion.

For acne to develop, the follicle must first become blocked. Only then does sebum accumulate in a closed, low-oxygen environment that allows bacterial lipase activity to dominate. C. acnes is a normal resident of the pilosebaceous unit. Its pathogenic role is not its presence, but its behaviour within an obstructed follicle.

Here, bacterial lipase degrades sebum triglycerides into free fatty acids. These free fatty acids are highly inflammatory. They initiate oxidative stress, immune activation and downstream inflammatory amplification. This is the precise point at which a microcomedone becomes a clinical lesion.

This sequence cannot occur in an open follicle. In an unobstructed unit, sebum drains, oxygen tension remains unfavourable for pathogenic bacterial behaviour and inflammatory escalation does not take place.

Reducing sebum production does not prevent this process. It simply reduces the amount of substrate while leaving the pathological mechanism intact.

Sebum is not pathological by default. It is a fundamental component of skin physiology. It contributes to barrier integrity, supports the cutaneous microbiome and plays a role in follicular homeostasis. Treating sebum as the enemy ignores its regulatory function and its interaction with the microbial ecosystem of the skin.

Aggressive or chronic sebum suppression carries consequences. These include barrier impairment, compensatory sebaceous dysregulation, microbiome disruption and increased inflammatory sensitivity. In acne-prone skin, driving sebum towards eradication can paradoxically increase reactivity and relapse rather than resolve disease.

Devices and treatments that focus on destroying sebaceous function may produce short-term reductions in surface oil. They do not address follicular obstruction, do not prevent bacterial lipase activity and do not interrupt the biochemical cascade that creates the lesion. In some cases, they risk creating a hostile, dysregulated cutaneous environment that perpetuates inflammation.

A more rational target is what happens to sebum inside the obstructed follicle.

SkinMed protocols focus on protecting sebum triglycerides from bacterial lipase degradation, converting bacterial activity into a self-limiting antimicrobial mechanism and modifying follicular pH to suppress inflammatory escalation. The objective is not to remove sebum, but to prevent it from becoming inflammatory.

Triethyl citrate binds bacterial lipase and protects triglycerides from degradation. When cleaved, it releases citric acid, reducing follicular pH to approximately 3.5. At this pH, C. acnes viability is dramatically reduced. Oligopeptide-10 weakens bacterial cell walls, increasing susceptibility to this acidic environment. Bacterial behaviour is neutralised without stripping the skin of a normal physiological function.

Acne severity is also driven by sebaceous sensitivity to dihydrotestosterone rather than oil volume alone. Increasing linoleic acid availability via ethyl linoleate reduces DHT sensitivity as DHT sensitivity is inversely proportional to linoleic acid levels in sebum. Ethyl Linoleate is also an inhibitor of 5 alpha reductase.